Chinese Journal of Lung Cancer (Jul 2024)

Progress of IL-21 and Tfh Mediated Immunotherapy in Non-small Cell Lung Cancer

  • Xingkai LIU,
  • Yifan ZHANG,
  • Xin ZHANG,
  • Gonghao HE,
  • Wenke CAI

DOI
https://doi.org/10.3779/j.issn.1009-3419.2024.101.19
Journal volume & issue
Vol. 27, no. 7
pp. 550 – 558

Abstract

Read online

Non-small cell lung cancer (NSCLC) is a prevalent and aggressive global malignancy. Conventional surgical treatments, radiotherapy, chemotherapy, and targeted therapies often fall short in halting disease progression due to inherent limitations, resulting in suboptimal prognosis. Despite the advent of immunotherapy drugs offering new hope for NSCLC treatment, current efficacy remains insufficient to meet all patient needs. Therefore, actively exploring novel immunotherapeutic approaches to further reduce mortality rates in NSCLC patients has become a crucial focus of NSCLC research. This article aims to systematically review the anti-tumor effects of interleukin-21 and follicular helper T cells in NSCLC immunotherapy by summarizing and analyzing relevant literatures from both domestic and international sources, as well as exploring the potential for enhancing NSCLC treatment prospects through immune checkpoint regulation via immunotherapeutic means.

Keywords